Early kynurenine pathway activation following cardiac arrest in rats, pigs, and humans

Resuscitation

Volumn 84, Issue 11, 2013, Pages 1604-1610

  Ristagno, Giuseppe ^a   Fries, Michael ^b   Brunelli, Laura ^a   Fumagalli, Francesca ^a   Bagnati, Renzo ^a   Russo, Ilaria ^a   Staszewsky, Lidia ^a   Masson, Serge ^a   Li Volti, Giovanni ^c,d   Zappalà, Agata ^c   Derwall, Matthias ^b   Brücken, Anne ^b   Pastorelli, Roberta ^a   Latini, Roberto ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

Brain injury; Cardiac arrest; Kynurenine pathway; Outcome; Post cardiac arrest syndrome; Tryptophan

Indexed keywords

3 HYDROXYANTHRANILIC ACID; BIOLOGICAL MARKER; KYNURENINE; TRYPTOPHAN;

ADULT; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEART ARREST; HUMAN; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; NONHUMAN; OUT OF HOSPITAL CARDIAC ARREST; OUTCOMES RESEARCH; PLASMA; PRIORITY JOURNAL; RAT; RESUSCITATION; SPECIES DIFFERENCE; SURVIVAL RATE; SWINE; TREATMENT OUTCOME;

BRAIN INJURY; CARDIAC ARREST; KYNURENINE PATHWAY; OUTCOME; POST CARDIAC ARREST SYNDROME; TRYPTOPHAN;

ANIMALS; CARDIOPULMONARY RESUSCITATION; CHROMATOGRAPHY, LIQUID; HEART ARREST; HEMODYNAMICS; HUMANS; KYNURENINE; MALE; MASS SPECTROMETRY; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE; SWINE;

EID: 84886770610     PISSN: 03009572     EISSN: 18731570     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2013.06.002     Document Type: Article

References (36)

1. Travers A.H., Rea T.D., Bobrow B.J., et al. Part 4: CPR Overview 2010 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2010, 122:S676-S684.
2. Lippert F.K., Raffay V., Georgiou M., Steen P.A., Bossaert L. European Resuscitation Council Guidelines for Resuscitation 2010 Section 10. The ethics of resuscitation and end-of-life decisions. Resuscitation 2010, 81:1445-1451.
3. Nolan J.P., Neumar R.W., Adrie C., et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation 2008, 79:350-379.
4. Schenenberger R.A., von Planta M., von Planta I. Survival after failed out of hospital resuscitation. Are further therapeutic efforts in the emergency department futile?. Arch Intern Med 1994, 154:2433-2437.
5. A randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. N Engl J Med 1986, 314:397-403. Brain Resuscitation Clinical Trial I Study Group.
6. Brown C.G., Martin D.R., Pepe P.E., et al. Comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. N Engl J Med 1992, 327:1051-1055.
7. Böttiger B.W., Grabner C., Bauer H., et al. Long term outcome after out-of-hospital cardiac arrest with physician staffed emergency medical services: the Utstein style applied to a midsized urban/suburban area. Heart 1999, 82:674-679.
8. Olasveengen T.M., Lund-Kordahl I., Steen P.A., Sunde K. Out-of hospital advanced life support with or without a physician: effects on quality of CPR and outcome. Resuscitation 2009, 80:1248-1252.
9. Adrie C., Laurent I., Monchi M., Cariou A., Dhainaou J.F., Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome. Curr Opin Crit Care 2004, 10:208-212.
10. Peberdy M.A., Callaway C.W., Neumar R.W., et al. Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010, 122:S768-S786.
11. Becker L.B., Weisfeldt M.L., Weil M.H., et al. The PULSE initiative: scientific priorities and strategic planning for resuscitation research and life saving therapies. Circulation 2002, 105:2562-2570.
12. Brunelli L., Ristagno G., Bagnati R., et al. A combination of untargeted and targeted metabolomics approaches unveils changes in the kynurenine pathway following cardiopulmonary resuscitation. Metabolomics 2013, in press. 10.1007/s11306-013-0506-0.
13. Wilson A., Morandi A., Girard T.D. et al: The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness. Crit Care Med 2012, 40:835-841.
14. Changsirivathanathamrong D., Wang Y., Rajbhandari D., et al. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. Crit Care Med 2011, 39:2678-2683.
15. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:702-721.
16. Huttunen R., Syrjänen J., Aittoniemi J., et al. High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients. Shock 2010, 33:149-154.
17. Fries M., Brücken A., Cizen A., et al. Combining xenon and mild therapeutic hypothermia preserves neurological function after prolonged cardiac arrest in pigs. Crit Care Med 2012, 40:1297-1303.
18. Stoppe C., Fries M., Rossaint R., et al. Blood levels of macrophage migration inhibitory factor after successful resuscitation from cardiac arrest. PLoS ONE 2012, 7:e33512.
19. Derwall M., Stoppe C., Brucken D., Rossaint R., Fries M. Changes in S-100 protein serum levels in survivors of out-of-hospital cardiac arrest treated with mild therapeutic hypothermia: a prospective, observational study. Crit Care 2009, 13:R58.
20. Sun S., Tang W., Song F., et al. The effects of epinephrine on outcomes of normothermic and therapeutic hypothermic cardiopulmonary resuscitation. Crit Care Med 2010, 38:2175-2180.
21. Fiordaliso F., Chimenti S., Staszewsky L., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2005, 102:2046-2051.
22. Clarke G., Fitzgerald P., Cryan J.F., et al. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol 2009, 9:6.
23. Wong P.T., Ong Y.P. Acute antidepressant-like and antianxiety-like effects of tryptophan in mice. Pharmacology 2001, 62:151-156.
24. Hékimian G., Baugnon T., Thuong M., et al. Cortisol levels and adrenal reserve after successful cardiac arrest resuscitation. Shock 2004, 22:116-119.
25. Darlington L.G., Mackay G.M., Forrest C.M., Stoy N., George C., Stone T.W. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci 2007, 26:2211-2221.
26. Neumar R.W. Molecular mechanisms of ischemic neuronal injury. Ann Emerg Med 2000, 36:483-506.
27. Stone T.W. The neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993, 45:309-379.
28. Brouns R., Verkerk R., Aerts T., et al. The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochem Res 2010, 35:1315-1322.
29. Sas K., Robotka H., Toldi J., Vécsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci 2007, 257:221-239.
30. Nozaki K., Beal M.F. Neuroprotective effects of l-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab 1992, 12:400-407.
31. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002, 1:609-620.
32. Cozzi A., Carpenedo R., Moroni F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3, 4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab 1999, 19:771-777.
33. Wang Y., Liu H., McKenzie G., et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 2010, 16:279-287.
34. Jung I.D., Lee M.G., Chang J.H., et al. Blockade of indoleamine 2,3-dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J Immunol 2009, 182:3146-3154.
35. Logters T.T., Laryea M.D., Altrichter J., et al. Increased plasma kynurenine values and kynurenine: tryptophan ratios after major trauma are early indicators for the development of sepsis. Shock 2009, 32:29-34.
36. Swardfager W., Herrmann N., Dowlati Y., et al. Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. Psychoneuroendocrinology 2009, 34:1560-1566.